Insider trade

Halozyme (HALO): CEO sold ~$580K

Helen Torley, CEO at Halozyme, sold ~$580K of Halozyme shares.

~$580K
Approx. value · 7,800 sh @ $74.33
736K
Holds after · shares reported
Traded
Sep 4, 2025
Filed
Sep 4, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jul 8, 2025Insider · 1 personInsiders: 2 sales (~$1.1M)
  2. Jul 9, 2025Insider · 1 personInsiders: 2 sales (~$1.1M)
  3. Jul 10, 2025Insider · 1 personInsiders: 2 sales (~$1.1M)
  4. Aug 11, 2025Insider · 1 personInsiders: 2 sales (~$1.3M)
  5. Aug 12, 2025Insider · 1 personInsiders: 2 sales (~$1.3M)
  6. Aug 13, 2025Insider · 1 personInsiders: 2 sales (~$1.3M)
  7. Sep 2, 2025Insider · 2 peopleInsiders: 6 sales (~$1.8M)
  8. Sep 3, 2025Insider · 1 personInsiders: 2 sales (~$1.5M)
  9. Sep 4, 2025 · this disclosureInsiderCEO sold ~$580K of HALO shares in the open market

What came next

  1. Sep 4, 2025Insider · 1 personInsiders: 2 sales (~$901K)
  2. Sep 10, 2025Insider · 1 personInsiders: 2 sales (~$1.5M)
  3. Sep 22, 2025Insider · 1 personInsiders: 2 sales (~$174K)
  4. Sep 30, 2025Company filing · Form 8-K · Material agreementSigned an important agreement
  5. Oct 1, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 1, 2025, Cortney Caudill was appointed as Senior Vice President, Chief Operating Officer of Halozyme Therapeutics, Inc. (the “Company”), effective immediately.”
  6. Nov 1, 2025InsiderOfficer sold ~$278K of HALO shares in the open market
  7. Nov 3, 2025Company filing · Form 8-K · Results, Executive changeChanged a top executive or board member, and reported its results“The Company announced today a transition plan in which Nicole LaBrosse, Senior Vice President and Chief Financial Officer (“CFO”) will continue to serve as the Company’s CFO until the earlier of when a new chief financial officer is hired, or until March 30, 2026 (the “Separation Date”) and then depart to pursue a new professional opportunity.”
  8. Nov 5, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 1 more item)
  9. Nov 6, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 1 more item)
  10. Nov 10, 2025Insider · 2 peopleInsiders: 3 sales (~$1.5M)
  11. Nov 11, 2025Insider · 1 personInsiders: 3 sales (~$1.4M)
  12. Nov 12, 2025Insider · 1 personInsiders: 3 sales (~$1.4M)
  13. Nov 18, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“(e) As previously disclosed, Halozyme Therapeutics, Inc. (“the Company”) announced a transition plan in which Nicole LaBrosse, Senior Vice President, Chief Financial Officer will continue to serve as the Company’s Chief Financial Officer until the earliest of when a new chief financial officer is hired, March 30, 2026 or such earlier date determined by the Company (the “Separation Date”) and then depart to pursue a…”
  14. Dec 1, 2025Insider · 2 peopleInsiders: 5 sales (~$1.2M)
  15. Dec 4, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 4, 2025, James Lang was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”). Mr. Lang was elected to the class of directors with terms ending at the Company’s annual meeting of stockholders in 2027.”
  16. Dec 4, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 4, 2025, the Compensation Committee of the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”) approved a performance-based restricted stock unit grant (the “PSU Grant”) for Dr. Helen Torley, Chief Executive Officer of the Company.”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Halozyme

For Halozyme, OQRO holds 39 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its HALO page.

Other recent filings by Helen Torley, PRESIDENT AND CEO

The full history of Helen Torley, PRESIDENT AND CEO is on the profile page.

How this filing works

Explore the data

Common questions

Which Halozyme (HALO) insider traded, and how much?

Helen Torley, CEO at Halozyme, sold ~$580K of Halozyme shares. 7,800 shares at $74.33.

When did it happen, and when was it made public?

Traded: Sep 4, 2025. Filed: Sep 4, 2025.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Halozyme recently?

For Halozyme, OQRO holds 39 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the HALO page.

Does this mean HALO stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Halozyme

Everything OQRO holds on this company is on its HALO page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data